In one study, EGFRvIII-targeting CAR T cells have been engineered to secrete TEAMs against wild-type EGFR, as antigen loss in tumors treated with EGFRvIII CAR alone is correlated with tumor persistence and amplification of wild-type EGFR [131]. This evidence concerns the gene EGFR and neoplasm.